



Healthcare Provider Webinar
Middlesex and London Region
May 16, 2023

Welcome

Presenter:

Dr. Alex Summers


Medical Officer of Health
Middlesex-London Health Unit

 @alexsummers4

Number of COVID-19 tests completed and percent positive by surveillance week

May 8, 2022 to May 6, 2023

This graph shows provincial testing data for COVID-19 over the previous 52 weeks.




Data source: Public Health Ontario- Ontario COVID-19 Data Tool, extracted 2023-05-16. Data current as of the end of day 2023-05-06. <https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/COVID-19-Data-Surveillance/COVID-19-Data-Tool?tab=overview>

Number of influenza tests performed and percent positive by surveillance week

May 8, 2022 to May 6, 2023

This graph shows provincial testing data for influenza over the previous 52 weeks.



**It's official... the WHO announces an end to the
COVID-19 global public health emergency!**

Thank you!

On behalf of the Health Unit and our community, thank you for
your awesome work and commitment throughout this
generational challenge.

Vaccine Return Reminder

- Expired or unusable publicly funded vaccine should be returned to the Health Unit on a regular basis.
- Please see today's eNewsletter for dates, times and locations, where vaccine can be returned.
- Vaccine returns must be accompanied by a completed ***Vaccine Return Form***, or they will not be accepted.

Two NEW Pneumococcal Vaccines Authorized by Health Canada

- Prevnar[®]20 (Pneu-C-20) and Vaxneuvance[®] (Pneu-C-15) are now available in Ontario as non-publicly funded vaccine options.
- Non-publicly funded vaccines are not available to order from the Health Unit for clients at Health Unit clinics. Most non-publicly funded vaccines require a prescription to obtain from a pharmacy. Depending on the age of the client and vaccine type, a pharmacist may also be able to administer the vaccine.

Pneumococcal Vaccine	Description	Authorized Age Groups	Recommendations and Publicly Funded Criteria
Prevnar 13[®] (Pneu-C-13)	Conjugate* vaccine providing protection against 13 serotypes of Streptococcus pneumoniae bacteria	6 weeks of age and older	Publicly funded for: <ul style="list-style-type: none"> • Infants and children 6 weeks to 4 years of age • High risk adults aged 50 and older
Vaxneuvance[®] (Pneu-C-15)	Conjugate* vaccine providing protection against 15 serotypes of Streptococcus pneumoniae bacteria	6 weeks of age and older	NOT publicly funded , however: <ul style="list-style-type: none"> • May be considered as interchangeable with Prevnar 13 for those 6 weeks to 17 years old
Prevnar[®]20 (Pneu-C-20)	Conjugate* vaccine providing protection against 20 serotypes of Streptococcus pneumoniae bacteria	18 years of age and older	NOT publicly funded , however, is recommended for: <ul style="list-style-type: none"> • The following adults that have not been previously vaccinated with a pneumococcal vaccine: <ul style="list-style-type: none"> ○ Adults 65 years of age and older ○ Adults 50 to 64 years of age at higher risk of pneumococcal disease ○ Adults 18 to 49 years of age with immunocompromising conditions • Adults 65 years of age and over who have received Pneumovax 23 alone or both Prevnar 13 and Pneumovax 23 if it has been at least 5 years since their last dose
Pneumovax[®]23 (Pneu-P-23)	Polysaccharide* vaccine providing protection against 23 serotypes of Streptococcus pneumoniae bacteria	2 years of age and older	Publicly funded for: <ul style="list-style-type: none"> • Adults 65 years of age and older • High risk individuals 2 to 64 years of age

*Conjugate vaccines trigger the immune system in a different way and offer more durable and longer lasting protection than polysaccharide vaccines.

Pneumococcal Vaccines


Pneumococcal Vaccine	Description	Authorized Age Groups	Recommendations and Publicly Funded Criteria
Pevnar 13[®] (Pneu-C-13)	Conjugate* vaccine providing protection against 13 serotypes of Streptococcus pneumoniae bacteria	6 weeks of age and older	Publicly funded for: <ul style="list-style-type: none"> • Infants and children 6 weeks to 4 years of age • High risk adults aged 50 and older
Vaxneuvance[®] (Pneu-C-15)	Conjugate* vaccine providing protection against 15 serotypes of Streptococcus pneumoniae bacteria	6 weeks of age and older	NOT publicly funded , however: <ul style="list-style-type: none"> • May be considered as interchangeable with Pevnar 13 for those 6 weeks to 17 years old
Pevnar[®]20 (Pneu-C-20)	Conjugate* vaccine providing protection against 20 serotypes of Streptococcus pneumoniae bacteria	18 years of age and older	NOT publicly funded , however, is recommended for: <ul style="list-style-type: none"> • The following adults that have not been previously vaccinated with a pneumococcal vaccine: <ul style="list-style-type: none"> ○ Adults 65 years of age and older ○ Adults 50 to 64 years of age at higher risk of pneumococcal disease ○ Adults 18 to 49 years of age with immunocompromising conditions • Adults 65 years of age and over who have received Pneumovax 23 alone or both Pevnar 13 and Pneumovax 23 if it has been at least 5 years since their last dose
Pneumovax[®]23 (Pneu-P-23)	Polysaccharide* vaccine providing protection against 23 serotypes of Streptococcus pneumoniae bacteria	2 years of age and older	Publicly funded for: <ul style="list-style-type: none"> • Adults 65 years of age and older • High risk individuals 2 to 64 years of age

*Conjugate vaccines trigger the immune system in a different way and offer more durable and longer lasting protection than polysaccharide vaccines.

PHO Rounds: The 2023 Ontario HIV Testing Guidelines

- This session will discuss the updated Ontario HIV testing guidelines, which introduces a four-pronged approach to testing that aims to help reach persons with undiagnosed HIV infection.
- By the end of this session, participants will be able to:
 - Identify population groups that should be tested for HIV according to the new Ontario HIV testing guidelines
 - Describe scenarios and conditions where it is appropriate to test (and retest) people for HIV; and
 - List additional HIV prevention interventions and when to recommend them.

You can sign up from the button within the eNewsletter



Sign up

Event Details:
Online webinar
Tuesday, May 23, 2023
12:00 p.m. to 1:00 p.m.
CME accredited

Details on how to join the webinar will be sent after registering for the event

[Click here](#)

Questions?

- Ask using chat function now, or after the webinar at:
healthcareproviders@mlhu.on.ca
- For urgent matters please call the Health Unit's main line at **519-663-5317**
- For more information
www.healthunit.com/healthcare-providers

